Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

ORIC

+ Watchlist+ Portfolio

Oric Pharmaceuticals, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$7.65
52-Week Range
$7.23 – $14.68
Market Cap
$800.27M
P/E (TTM)
—
EPS (TTM)
-1.44
Dividend Yield
0.00%
Advanced Metrics
Price/Book
2.36
PEG Ratio
—
Return on Equity
-41.76%
Return on Assets
-26.79%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
11.09
Debt/Equity
0.02
Total Debt
$5.96M
Free Cash Flow
$-80.36M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$539.66M

Market Snapshot

About

Oric Pharmaceuticals is a clinical-stage oncology biotechnology company focused on developing therapies to overcome drug resistance in cancer. The company advances precision medicines targeting cancer resistance mechanisms, including programs focused on hormone receptor-positive breast cancer and prostate cancer.